Skip to content
PharmaManufacturingIQ

Shaping the future of biopharma with emerging DNA formats

Jill Makin, Ph.D., chief scientific officer, Touchlight highlights how emerging DNA formats are shaping the future of biopharma.

By Olivia Friett
Shaping the future of biopharma with emerging DNA formats
Published: | 4 min read
Share to X Share to Bluesky Share to Facebook Share to LinkedIn Share by email

Jill Makin, Ph.D., chief scientific officer, Touchlight highlights how emerging DNA formats are shaping the future of biopharma.

Touchlight

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information